231 related articles for article (PubMed ID: 27588486)
1. Race-related differences in antibody responses to the inactivated influenza vaccine are linked to distinct pre-vaccination gene expression profiles in blood.
Kurupati R; Kossenkov A; Haut L; Kannan S; Xiang Z; Li Y; Doyle S; Liu Q; Schmader K; Showe L; Ertl H
Oncotarget; 2016 Sep; 7(39):62898-62911. PubMed ID: 27588486
[TBL] [Abstract][Full Text] [Related]
2. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
[TBL] [Abstract][Full Text] [Related]
3. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
Front Immunol; 2018; 9():2465. PubMed ID: 30405641
[No Abstract] [Full Text] [Related]
4. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
[TBL] [Abstract][Full Text] [Related]
5. Decreased ratio of influenza-specific IgG versus IgM in response to influenza vaccination in antiretroviral-treated HIV-infected African Americans compared to Caucasians, and its direct correlation with the percentages of peripheral Tfh cells.
Ma P; Luo Z; Qian J; Yan Z; Zhang L; Martin L; Wang Z; Xia H; Yu F; Jiang W
Vaccine; 2020 Feb; 38(8):1998-2004. PubMed ID: 31948820
[TBL] [Abstract][Full Text] [Related]
6. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
[TBL] [Abstract][Full Text] [Related]
7. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine compared with two trivalent inactivated influenza vaccines containing alternate B strains in adults: A phase 3, randomized noninferiority study.
Treanor JT; Albano FR; Sawlwin DC; Graves Jones A; Airey J; Formica N; Matassa V; Leong J
Vaccine; 2017 Apr; 35(15):1856-1864. PubMed ID: 28302411
[TBL] [Abstract][Full Text] [Related]
9. BTLA expression declines on B cells of the aged and is associated with low responsiveness to the trivalent influenza vaccine.
Kannan S; Kurupati RK; Doyle SA; Freeman GJ; Schmader KE; Ertl HC
Oncotarget; 2015 Aug; 6(23):19445-55. PubMed ID: 26277622
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional signatures of influenza A/H1N1-specific IgG memory-like B cell response in older individuals.
Haralambieva IH; Ovsyannikova IG; Kennedy RB; Zimmermann MT; Grill DE; Oberg AL; Poland GA
Vaccine; 2016 Jul; 34(34):3993-4002. PubMed ID: 27317456
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
[TBL] [Abstract][Full Text] [Related]
12. Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children.
Cao RG; Suarez NM; Obermoser G; Lopez SM; Flano E; Mertz SE; Albrecht RA; García-Sastre A; Mejias A; Xu H; Qin H; Blankenship D; Palucka K; Pascual V; Ramilo O
J Infect Dis; 2014 Jul; 210(2):224-33. PubMed ID: 24495909
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
Pepin S; Dupuy M; Borja-Tabora CFC; Montellano M; Bravo L; Santos J; de Castro JA; Rivera-Medina DM; Cutland C; Ariza M; Diez-Domingo J; Gonzalez CD; Martinón-Torres F; Papadopoulou-Alataki E; Theodoriadou M; Kazek-Duret MP; Gurunathan S; De Bruijn I;
Vaccine; 2019 Mar; 37(13):1876-1884. PubMed ID: 30558818
[TBL] [Abstract][Full Text] [Related]
14. Hemagglutinin-specific CD4
Tan S; Zhang S; Wu B; Zhao Y; Zhang W; Han M; Wu Y; Shi G; Liu Y; Yan J; Wu G; Wang H; Gao GF; Zhu F; Liu WJ
Vaccine; 2017 Oct; 35(42):5644-5652. PubMed ID: 28917539
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
[TBL] [Abstract][Full Text] [Related]
16. Antibody-dependent cell-mediated cytotoxicity antibody responses to inactivated and live-attenuated influenza vaccination in children during 2014-15.
Florek K; Mutschler J; McLean HQ; King JP; Flannery B; Belongia EA; Friedrich TC
Vaccine; 2020 Feb; 38(8):2088-2094. PubMed ID: 31753674
[TBL] [Abstract][Full Text] [Related]
17. Distinct patterns of B-cell activation and priming by natural influenza virus infection versus inactivated influenza vaccination.
He XS; Holmes TH; Sanyal M; Albrecht RA; García-Sastre A; Dekker CL; Davis MM; Greenberg HB
J Infect Dis; 2015 Apr; 211(7):1051-9. PubMed ID: 25336731
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older.
Greenberg DP; Robertson CA; Talbot HK; Decker MD
Hum Vaccin Immunother; 2017 Sep; 13(9):2058-2064. PubMed ID: 28700265
[TBL] [Abstract][Full Text] [Related]
19. Antibody responses induced by trivalent inactivated influenza vaccine among pregnant and non-pregnant women in Thailand: A matched cohort study.
Nakphook S; Patumanond J; Shrestha M; Prasert K; Chittaganpitch M; Mott JA; Praphasiri P
PLoS One; 2021; 16(6):e0253028. PubMed ID: 34106994
[TBL] [Abstract][Full Text] [Related]
20. Early Changes in Interferon Gene Expression and Antibody Responses Following Influenza Vaccination in Pregnant Women.
Giacomelli Cao R; Christian L; Xu Z; Jaramillo L; Smith B; Karlsson EA; Schultz-Cherry S; Mejias A; Ramilo O
J Infect Dis; 2022 Jan; 225(2):341-351. PubMed ID: 34197595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
